The Sigma-Chemist Warehouse merger formally completed on 12 February 2025. This report provides our pro-forma updated forecasts and model for the combined entity. We also explore three bull and bear arguments on the stock given its lofty valuation still makes it difficult for us to have anything but a Sell rating.

Chemist Warehouse has provided a trading update for the 1H25 results last week subsequent to shareholder approval of the merger with Sigma Healthcare. The 1H25 results are very strong with profit margins up 138bp (on network sales) in 1H25. What’s driving results? While not disclosed, we estimate more than half comes from higher gross margins with a benefit from the new Sigma supply agreement. We expect FY25e EBIT margins to be up 101bp. We now set our long-term EBIT margin for Chemist Warehouse at 8.2% of network sales compared with 7.4% previously.